# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘251...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.